Literature DB >> 7140120

Comparative serum prednisone and prednisolone concentrations following administration to patients with chronic active liver disease.

M Uribe, W H Summerskill, V L Go.   

Abstract

Following administration of equivalent oral doses (30mg) of either prednisone or prednisolone to 5 patients with chronic active liver disease who had failed to respond to therapy, 5 patients with chronic active liver disease in remission induced by prednisone, and 7 healthy volunteers, corticosteroid concentrations were measured in both serum and urine by radioimmunoassay. Prednisone and prednisolone concentrations in the urine were very similar in all groups, regardless of the drug given. After either treatment, the peak serum concentration and area under the prednisolone serum concentration-time curve were 4 to 5 times those of prednisone. Slight differences among the 3 groups studied were seen in prednisone and prednisolone pharmacokinetics, but none was significant. It is concluded that the use of prednisone instead of prednisolone to treat chronic active liver disease can not be implicated as a cause of treatment failure. Indeed, this study suggests that either medication is effective, and this is supported by serum concentrations which suggest a rapid interconversion equilibrium between the 2 corticosteroids.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7140120     DOI: 10.2165/00003088-198207050-00005

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  14 in total

1.  Comparative serum prednisone and prednisolone concentrations following prednisone or prednisolone administration to beagle dogs.

Authors:  W A Colburn; C R Sibley; R H Buller
Journal:  J Pharm Sci       Date:  1976-07       Impact factor: 3.534

2.  Effect of liquid diet on serum protein binding and prednisolone concentrations after oral prednisone.

Authors:  M Uribe; S W Schalm; W H Summerskill; V L Go
Journal:  Gastroenterology       Date:  1976-08       Impact factor: 22.682

3.  Failure of customary treatment in chronic active liver disease: causes and management.

Authors:  S W Schalm; H V Ammon; W H Summerskill
Journal:  Ann Clin Res       Date:  1976-06

4.  Oral prednisone for chronic active liver disease: dose responses and bioavailability studies.

Authors:  M Uribe; S W Schalm; W H Summerskill; V L Go
Journal:  Gut       Date:  1978-12       Impact factor: 23.059

5.  Prednisone or prednisolone for the treatment of chronic active hepatitis? A comparison of plasma availability.

Authors:  M Davis; R Williams; J Chakraborty; J English; V Marks; G Ideo; S Tempini
Journal:  Br J Clin Pharmacol       Date:  1978-06       Impact factor: 4.335

6.  Development of radioimmunoassays for prednisone and prednisolone. Application to studies of hepatic metabolism of prednisone.

Authors:  S W Schalm; W H Summerskill; V L Go
Journal:  Mayo Clin Proc       Date:  1976-12       Impact factor: 7.616

Review 7.  Corticosteroid pharmacokinetics in liver disease.

Authors:  M Uribe; V L Go
Journal:  Clin Pharmacokinet       Date:  1979 May-Jun       Impact factor: 6.447

8.  Corticosteroids in liver disease: studies on the biological conversion of prednisone to prednisolone and plasma protein binding.

Authors:  L W Powell; E Axelsen
Journal:  Gut       Date:  1972-09       Impact factor: 23.059

9.  Prednisone for chronic active liver disease: pharmacokinetics, including conversion to prednisolone.

Authors:  S W Schalm; W H Summerskill; V L Go
Journal:  Gastroenterology       Date:  1977-05       Impact factor: 22.682

10.  Decreased bioavailability of prednisone due to antacids in patients with chronic active liver disease and in healthy volunteers.

Authors:  M Uribe; C Casian; S Rojas; J G Sierra; V L Go
Journal:  Gastroenterology       Date:  1981-04       Impact factor: 22.682

View more
  4 in total

Review 1.  Emerging opportunities for site-specific molecular and cellular interventions in autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2010-01-27       Impact factor: 3.199

Review 2.  Guide to drug dosage in hepatic disease.

Authors:  N M Bass; R L Williams
Journal:  Clin Pharmacokinet       Date:  1988-12       Impact factor: 6.447

Review 3.  Acute and acute severe (fulminant) autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2012-10-23       Impact factor: 3.199

Review 4.  Drug therapy in the management of type 1 autoimmune hepatitis.

Authors:  A J Czaja
Journal:  Drugs       Date:  1999-01       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.